Andros Pharmaceuticals Co.,Ltd (6917) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Andros Pharmaceuticals Co.,Ltd TWD 6.15, price TWD 34.50, upside -82.2%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Andros Pharmaceuticals Co.,Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies.
Show more
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
Stock analysis
Andros Pharmaceuticals Co.,Ltd (6917) currently trades at 34.50 TWD, while our model-based Fair Value estimate is 6.15 TWD, 82.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 4.06 TWD (bear) to 7.68 TWD (bull), the price of 34.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Andros Pharmaceuticals Co.,Ltd reported revenue of 5.5M TWD in FY2025 versus 13.3M TWD in FY2021, a compound −19.7%/yr. Reported net income was −53.8M TWD in FY2025.
Key figures
Market cap 1.9B TWD (≈ $60.0M) · EPS (TTM) −1.16 TWD · Return on assets (EBIT) −18.1% · Free cash flow −46.4M TWD · Net cash 16.8M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −82%, 6917 screens richer than that median.
Fair Value models
Bear 4.06 TWDFair Value 6.15 TWDBull 7.68 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Start year 2020 (pandemic)
’20
’21
’22
’23
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,298.7% (2020) → −1,363.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Andros Pharmaceuticals Co.,Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−82.2% · Bottom 25%
Profitability
Return on assets0.0% · Above median
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Andros Pharmaceuticals Co.,Ltd (6917) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6.15 TWD versus a price of 34.50 TWD, about −82% upside (overvalued).
What is the fair value of 6917?
Our model-based fair value for Andros Pharmaceuticals Co.,Ltd is 6.15 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 34.50 TWD.
What is the quality score of 6917?
Andros Pharmaceuticals Co.,Ltd has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Andros Pharmaceuticals Co.,Ltd (6917)?
Our model-based price target is the fair value of 6.15 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 4.06 TWD, optimistic scenario 7.68 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Andros Pharmaceuticals Co.,Ltd stock forecast for 2026?
Our models put fair value at 6.15 TWD, about −82% upside versus a price of 34.50 TWD (overvalued). Cautious scenario 4.06 TWD, optimistic scenario 7.68 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Andros Pharmaceuticals Co.,Ltd (6917)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Andros Pharmaceuticals Co.,Ltd it is 6.15 TWD per share (as of Sep 24, 2026), against a price of 34.50 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Andros Pharmaceuticals Co.,Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6917 trades above its calculated fair value: price 34.50 TWD, fair value 6.15 TWD, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6917?
No. The price is what the market pays today (34.50 TWD); the fair value is what the company's own numbers justify (6.15 TWD). For Andros Pharmaceuticals Co.,Ltd the two are 28.35 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Andros Pharmaceuticals Co.,Ltd worth?
The market values Andros Pharmaceuticals Co.,Ltd at about 1.9B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 34.50 TWD; our models calculate a fair value of 6.15 TWD per share.
What do the bullish and bearish scenarios say about 6917?
Our models span a range for Andros Pharmaceuticals Co.,Ltd: cautious scenario 4.06 TWD, base 6.15 TWD, optimistic 7.68 TWD per share (as of Sep 24, 2026, price 34.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
Which stocks are comparable to Andros Pharmaceuticals Co.,Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Andros Pharmaceuticals Co.,Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 34.50 TWD, calculated fair value 6.15 TWD (−82%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6917 calculated?
We run Andros Pharmaceuticals Co.,Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.15 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Andros Pharmaceuticals Co.,Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Andros Pharmaceuticals Co.,Ltd (6917)?
The closing price on Oct 2, 2026 was 34.50 TWD. Our model-based fair value is 6.15 TWD, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Andros Pharmaceuticals Co.,Ltd right now?
The price sits above even our optimistic bull case (7.68 TWD). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4.06 TWD to 7.68 TWD) leaves room in how you read the outcome.
Key figures of Andros Pharmaceuticals Co.,Ltd
How large is the market capitalisation of Andros Pharmaceuticals Co.,Ltd (6917)?
The market capitalisation of Andros Pharmaceuticals Co.,Ltd is 1.9B TWD (≈ $60.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Andros Pharmaceuticals Co.,Ltd (6917)?
Earnings per share at Andros Pharmaceuticals Co.,Ltd are −1.16 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Andros Pharmaceuticals Co.,Ltd (6917)?
On an EBIT basis the return on assets of Andros Pharmaceuticals Co.,Ltd is −18.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Andros Pharmaceuticals Co.,Ltd (6917) generate?
The free cash flow of Andros Pharmaceuticals Co.,Ltd is −46.4M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Andros Pharmaceuticals Co.,Ltd (6917) hold?
Andros Pharmaceuticals Co.,Ltd holds more cash than debt, 16.8M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Andros Pharmaceuticals Co.,Ltd in the live analysis
One click puts Andros Pharmaceuticals Co.,Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
